Catalent clinical supply plant opens its doors in China

- Last updated on GMT

Catalent clinical supply plant opens its doors in China
Catalent has cut the ribbon on its Clinical Supply facility in China just months after construction began.

Back in February, this publication reported news of Catalent’s expansion into China with the acquisition of a softgel firm and a joint venture with local CRO ShangPharma Corporation to provide end-to-end solutions for clinical trials from a new facility in Shanghai.

Last week, the latter was completed less than nine months after construction began and the 31,000 sq ft clinical trial site opened its doors.

China is a fast growing market for the pharmaceutical industry and a market that Catalent will continue to invest in,” ​saidScott Houlton, President of Development and Clinical Services at Catalent, at a ceremony last week.

I’m excited to see this strategy implemented and the new site open for business. It is a great addition to Catalent’s global clinical supply network and will help to better serve our customers increasing need for clinical trials in Asia.”

Initially, the site would employ more than twenty staff by the end of this year, spokesman Chris Halling told this publication back in February, but as the Clinical Supply activity in China and Asia grows, so too will the workforce.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers